Further studies on a larger range of samples, including malignant and benign thyroid tumors, are likely to clarify whether the assessment of the methylation state of CpG sites +134, +137, +142, +147 and +156, possibly in combination with Gal-3 immunostaining, may be a candidate analysis which substantially contributes to increasing the accuracy of the currently used markers for distinguishing thyroid cancer from benign thyroid adenomas. Here, LGALS3 is linked to thyroid gland carcinoma.